<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176784</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0404</org_study_id>
    <secondary_id>R01HL109031</secondary_id>
    <secondary_id>A534253</secondary_id>
    <secondary_id>SMPH/MEDICINE/GEN INT MD</secondary_id>
    <secondary_id>Protocol Version 6/11/2020</secondary_id>
    <nct_id>NCT03176784</nct_id>
  </id_info>
  <brief_title>UW Quitting Using Intensive Treatment Study (QUITS)</brief_title>
  <acronym>QUITS</acronym>
  <official_title>UW Quitting Using Intensive Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will determine whether two highly promising modifications to varenicline&#xD;
      treatment (i.e. use of a nicotine patch adjuvant and extended 24-week duration) produce&#xD;
      superior smoking outcomes when they are either used together or alone. Despite their promise,&#xD;
      the proposed modifications have never been experimentally evaluated relative to standard&#xD;
      varenicline pharmacotherapy. Thus, this innovative research will produce novel evidence&#xD;
      regarding how best to help smokers quit, and thereby address the leading cause of preventable&#xD;
      mortality and morbidity related to cardiovascular and pulmonary diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Building on our recent NHLBI-funded publication in JAMA (see references below) that described&#xD;
      the modest effectiveness of varenicline pharmacotherapy, this study will use a 2 X 2&#xD;
      factorial design to evaluate two different medication use strategies on their ability to&#xD;
      markedly enhance varenicline effectiveness in a large cohort of current smokers. Smokers&#xD;
      (N=1000) will be randomly assigned to one of two levels for each of two factors: 1) an&#xD;
      Adjuvant factor (varenicline + placebo patch versus varenicline + nicotine patch), and 2) a&#xD;
      Duration factor (12 versus 24 weeks of active medication). Thus, this factorial design yields&#xD;
      a &quot;standard&quot; varenicline treatment (12 weeks of active varenicline and 12 weeks of placebo&#xD;
      varenicline + 24 weeks of placebo patch), and 3 enhanced treatments: 1) 12 weeks of active&#xD;
      varenicline and 12 weeks of placebo varenicline + 24 weeks of active patch, 2) 24-weeks of&#xD;
      active varenicline + 24 weeks of placebo patch, and 3) 24 weeks of active varenicline + 24&#xD;
      weeks of active patch.&#xD;
&#xD;
      Both treatment modifications, longer duration therapy and use of a nicotine replacement&#xD;
      therapy (NRT) adjuvant, have produced some quite promising effects. However, in both cases&#xD;
      these modifications have been little researched, their effects are not consistently positive,&#xD;
      and they have not been implemented in a potentially optimal manner. We will implement each&#xD;
      modification in an innovative manner designed to enhance its effectiveness. In addition, all&#xD;
      participants will be given counseling that supports adherent medication use and that is&#xD;
      readily translatable to healthcare settings. The scientific rigor of this work will be&#xD;
      enhanced by the use of placebo medication, a large sample, and a factorial design. The latter&#xD;
      will allow us to test both the main and interaction effects of the experimental factors. We&#xD;
      will also be able to compare each enhanced treatment with standard 12-week varenicline-only&#xD;
      therapy to determine whether any of these medication use strategies significantly enhances&#xD;
      treatment effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2017</start_date>
  <completion_date type="Actual">July 9, 2020</completion_date>
  <primary_completion_date type="Actual">July 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Double Blinded Placebo Controlled Factorial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Active and placebo medications are identical in appearance. Medication labeling and the dispensing protocol are designed to prevent participants and care providers from knowing if the medication is active or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>52-Week Point-Prevalence Abstinence</measure>
    <time_frame>Assessed 52 weeks after quit date</time_frame>
    <description>Biochemically-confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>23-Week Point-Prevalence Abstinence</measure>
    <time_frame>Assessed 23 weeks after quit date</time_frame>
    <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>52-Week Prolonged Abstinence</measure>
    <time_frame>Assessed 52 weeks after quit date</time_frame>
    <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 52 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>23-Week Prolonged Abstinence</measure>
    <time_frame>Assessed 23 weeks after quit date</time_frame>
    <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 23 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1251</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Varenicline + Patch Standard Duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline Only Standard Duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline + Patch Extended Duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline Only Extended Duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
    <arm_group_label>Varenicline + Patch Extended Duration</arm_group_label>
    <arm_group_label>Varenicline + Patch Standard Duration</arm_group_label>
    <arm_group_label>Varenicline Only Extended Duration</arm_group_label>
    <arm_group_label>Varenicline Only Standard Duration</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
    <arm_group_label>Varenicline + Patch Extended Duration</arm_group_label>
    <arm_group_label>Varenicline + Patch Standard Duration</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
    <arm_group_label>Varenicline + Patch Standard Duration</arm_group_label>
    <arm_group_label>Varenicline Only Extended Duration</arm_group_label>
    <arm_group_label>Varenicline Only Standard Duration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Pill</intervention_name>
    <description>Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
    <arm_group_label>Varenicline + Patch Standard Duration</arm_group_label>
    <arm_group_label>Varenicline Only Standard Duration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Participants must: plan to stay in the area for the next 12 months, ability to read and&#xD;
        write in English, smoke on average ≥5 cigarettes per day over the last 6 months, be ≥18&#xD;
        years old, desire to quit smoking but not be engaged currently in cessation treatment,&#xD;
        report no use of pipe tobacco, cigars, snuff, e-cigarettes or chew in the last 30 days,&#xD;
        have reliable phone access, willing and able to use both nicotine patch and varenicline,&#xD;
        access to transportation to come to our clinic and, if female, not be pregnant and be using&#xD;
        an acceptable birth control method/ method to prevent pregnancy. Smoking will be&#xD;
        biochemically confirmed via a carbon monoxide (CO) breath test at the orientation session&#xD;
        visit. Potential participants must have a CO test result of ≥5ppm for eligibility to&#xD;
        participate.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Current treatment for schizophrenia or a psychotic disorder; suicidal ideation in the past&#xD;
        12 months; history of suicidal attempts within the last 10 years; on dialysis or being told&#xD;
        you have severe kidney disease; hospitalization for a stroke, heart attack, congestive&#xD;
        heart failure or uncontrolled diabetes mellitus within the past year; history of seizure&#xD;
        within the last year; currently taking Wellbutrin, Zyban, or Buproprion (Contrave is a&#xD;
        weight-loss drug that has Wellbutrin in it) for reasons other than to quit smoking or&#xD;
        taking to help quit smoking and not willing to stop for duration of the study; currently&#xD;
        using any form of nicotine replacement (e.g., nicotine patch, nicotine gum, nicotine&#xD;
        lozenge) or using Chantix or varenicline and not willing to stop for duration of the study;&#xD;
        had a reaction to the nicotine patch that prevented them from continuing to use it; or&#xD;
        currently participating in another smoking cessation study.&#xD;
&#xD;
        Pregnancy:&#xD;
&#xD;
        Even though we screen out participants who are pregnant, plan to become pregnant, nursing,&#xD;
        or are unwilling to take steps to avoid pregnancy, there is a chance that a participant&#xD;
        eligible at consent could become pregnant later. She would then be considered part of a&#xD;
        vulnerable group. Given the longitudinal nature of the research, a participant who becomes&#xD;
        pregnant after enrolling will be given the choice of whether to 1) continue in the study&#xD;
        (for counseling and other assessments) and agree to immediately stop taking study meds for&#xD;
        the remaining duration of the study and return any unused medications, OR 2) withdraw. No&#xD;
        further medications will be given to this study participant while in the study.&#xD;
&#xD;
        Incarcerated Individuals:&#xD;
&#xD;
        Incarcerated individuals will not be enrolled in this study. However, given the&#xD;
        longitudinal nature of the research, participants could be incarcerated for periods during&#xD;
        their participation. If study staff learn that a participant is incarcerated at a time&#xD;
        point before or at their Week 8 phone call, the participant will be withdrawn from the&#xD;
        study. If study staff learn that a participant is incarcerated subsequent to Week 8, the&#xD;
        participant will not be withdrawn unless that incarceration will take them beyond the study&#xD;
        period. In that case, staff will not contact the participant while incarcerated and will&#xD;
        not provide any treatment (counseling or medication) nor conduct any assessments during the&#xD;
        period of incarceration. Services and assessments will be re-initiated if the participant&#xD;
        is released at a later study time point.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy B Baker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UW Center For Tobacco Research and Intervention</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Center for Tobacco Research and Intervention</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ctri.wisc.edu/</url>
    <description>UW Center for Tobacco Research and Intervention website</description>
  </link>
  <reference>
    <citation>Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, Fiore MC. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. JAMA. 2016 Jan 26;315(4):371-9. doi: 10.1001/jama.2015.19284.</citation>
    <PMID>26813210</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <results_first_submitted>May 4, 2021</results_first_submitted>
  <results_first_submitted_qc>May 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varenicline</keyword>
  <keyword>Nicotine Patch</keyword>
  <keyword>Quit Smoking</keyword>
  <keyword>Tobacco</keyword>
  <keyword>Cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data set will be posted by UW-CTRI in accord with NHLBI policies</ipd_description>
    <ipd_time_frame>12 months after publication of the primary outcome paper.</ipd_time_frame>
    <ipd_access_criteria>Prior written data request to the PI.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03176784/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03176784/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred via community outreach (e.g., social networking sites, radio, TV, newspaper). Interested respondents were called and screened for initial eligibility; those eligible attended a group orientation session that entailed: final eligibility assessment, written informed consent, baseline assessments, biochemical confirmation of smoking status, and randomization. Study visits were in Madison and Milwaukee, WI. First participant enrolled on 11/11/17; study completed on 7/9/20.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Varenicline + Patch Standard Duration</title>
          <description>Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
        </group>
        <group group_id="P2">
          <title>Varenicline Only Standard Duration</title>
          <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
        </group>
        <group group_id="P3">
          <title>Varenicline + Patch Extended Duration</title>
          <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
        </group>
        <group group_id="P4">
          <title>Varenicline Only Extended Duration</title>
          <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="315"/>
                <participants group_id="P3" count="311"/>
                <participants group_id="P4" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="198"/>
                <participants group_id="P4" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="113"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline + Patch Standard Duration</title>
          <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
        </group>
        <group group_id="B2">
          <title>Varenicline Only Standard Duration</title>
          <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
        </group>
        <group group_id="B3">
          <title>Varenicline + Patch Extended Duration</title>
          <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
        </group>
        <group group_id="B4">
          <title>Varenicline Only Extended Duration</title>
          <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="314"/>
            <count group_id="B2" value="315"/>
            <count group_id="B3" value="311"/>
            <count group_id="B4" value="311"/>
            <count group_id="B5" value="1251"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="12.4"/>
                    <measurement group_id="B2" value="48.6" spread="11.4"/>
                    <measurement group_id="B3" value="48.9" spread="12.3"/>
                    <measurement group_id="B4" value="49.9" spread="11.5"/>
                    <measurement group_id="B5" value="49.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="166"/>
                    <measurement group_id="B4" value="167"/>
                    <measurement group_id="B5" value="675"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="144"/>
                    <measurement group_id="B5" value="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="297"/>
                    <measurement group_id="B3" value="285"/>
                    <measurement group_id="B4" value="297"/>
                    <measurement group_id="B5" value="1164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="214"/>
                    <measurement group_id="B5" value="867"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="315"/>
                    <measurement group_id="B3" value="311"/>
                    <measurement group_id="B4" value="311"/>
                    <measurement group_id="B5" value="1251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>52-Week Point-Prevalence Abstinence</title>
        <description>Biochemically-confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
        <time_frame>Assessed 52 weeks after quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Patch Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Only Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O3">
            <title>Varenicline + Patch Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline Only Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
          </group>
        </group_list>
        <measure>
          <title>52-Week Point-Prevalence Abstinence</title>
          <description>Biochemically-confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.66</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.85</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>23-Week Point-Prevalence Abstinence</title>
        <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
        <time_frame>Assessed 23 weeks after quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Patch Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Only Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O3">
            <title>Varenicline + Patch Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline Only Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
          </group>
        </group_list>
        <measure>
          <title>23-Week Point-Prevalence Abstinence</title>
          <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow-up day, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.44</p_value>
            <p_value_desc>Study site (Madison vs Milwaukee) was included as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.61</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.12</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>52-Week Prolonged Abstinence</title>
        <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 52 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
        <time_frame>Assessed 52 weeks after quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Patch Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Only Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O3">
            <title>Varenicline + Patch Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline Only Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
          </group>
        </group_list>
        <measure>
          <title>52-Week Prolonged Abstinence</title>
          <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 52 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.43</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.37</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.81</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>23-Week Prolonged Abstinence</title>
        <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 23 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
        <time_frame>Assessed 23 weeks after quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline + Patch Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Only Standard Duration</title>
            <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
          </group>
          <group group_id="O3">
            <title>Varenicline + Patch Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline Only Extended Duration</title>
            <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
          </group>
        </group_list>
        <measure>
          <title>23-Week Prolonged Abstinence</title>
          <description>Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) from week 2 post-quit through week 23 post-quit, confirmed with an exhaled carbon monoxide reading of less than or equal to 5 ppm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="315"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.65</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.60</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.86</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Study site (Madison vs Milwaukee) was included as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected and tabulated for the first 12 weeks of treatment.</time_frame>
      <desc>Some participants did not complete the adverse event assessments. The denominators used to calculate the percentage of participants reporting a given adverse event in each of the four conditions equal the number of participants responding to the adverse event assessment inquiry. Thus, the denominators do not equal the number of participants who started the study in each of the four conditions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Varenicline + Patch Standard Duration</title>
          <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Nicotine Patches:&#xD;
Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
        </group>
        <group group_id="E2">
          <title>Varenicline Only Standard Duration</title>
          <description>Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID&#xD;
Standard Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.&#xD;
Placebo Pill: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)</description>
        </group>
        <group group_id="E3">
          <title>Varenicline + Patch Extended Duration</title>
          <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Nicotine Patches:&#xD;
14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit.&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Nicotine patch: 14 mg and 7 mg nicotine patches used. See arms for specific durations.</description>
        </group>
        <group group_id="E4">
          <title>Varenicline Only Extended Duration</title>
          <description>Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22&#xD;
Extended Condition Placebo Patches:&#xD;
Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit&#xD;
Varenicline: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)&#xD;
Placebo Patch: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="311"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="311"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="295"/>
                <counts group_id="E4" subjects_affected="160" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="92" subjects_affected="92" subjects_at_risk="305"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="300"/>
                <counts group_id="E3" events="73" subjects_affected="73" subjects_at_risk="295"/>
                <counts group_id="E4" events="95" subjects_affected="95" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="305"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="300"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="295"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="93" subjects_affected="93" subjects_at_risk="305"/>
                <counts group_id="E2" events="88" subjects_affected="88" subjects_at_risk="300"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="295"/>
                <counts group_id="E4" events="83" subjects_affected="83" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Changes in Mood</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="305"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="300"/>
                <counts group_id="E3" events="53" subjects_affected="53" subjects_at_risk="295"/>
                <counts group_id="E4" events="50" subjects_affected="50" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching/Hives</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="305"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="300"/>
                <counts group_id="E3" events="39" subjects_affected="39" subjects_at_risk="295"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="305"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="300"/>
                <counts group_id="E3" events="51" subjects_affected="51" subjects_at_risk="295"/>
                <counts group_id="E4" events="30" subjects_affected="30" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stevens S. Smith, Ph.D.</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health</organization>
      <phone>608-262-7563</phone>
      <email>sss@ctri.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

